Investors might want to bet on Alnylam Pharmaceuticals (ALNY) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.Analysts' growing optimism on the earnings prospects of this RNA interference drug developer is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation betwe ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [3] Performance Metrics - Over the past week, ALNY shares increased by 0.9%, while the Zacks Medical - Biomedical and Genetics industry declined by 0.34% [5] - In the last quarter, ALNY shares rose by 44.29%, and over the past year, they gained 63.33%, significantly outperforming the S&P 500, which increased by 6.33% and 14.66% respectively [6] - The average 20-day trading volume for ALNY is 1,102,099 shares, indicating a bullish trend when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for ALNY have been revised upwards, while none have been lowered, raising the consensus estimate from $3.35 to $3.98 [9] - For the next fiscal year, two estimates have increased, while one has decreased, reflecting a generally positive earnings outlook [9] Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a promising investment opportunity with a Momentum Score of A [11]

Core Insights - Alnylam Pharmaceuticals (ALNY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum [1][2] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively impact its stock price [2][3] Current-Quarter Estimate Revisions - The company is projected to earn $0.50 per share for the current quarter, indicating a year-over-year increase of +200.0% [6] - The Zacks Consensus Estimate for Alnylam has risen by 62.96% over the last 30 days, with four estimates increasing and no negative revisions [6] Current-Year Estimate Revisions - For the full year, Alnylam is expected to earn $1.61 per share, representing a year-over-year change of +8,150.0% [7] - The trend for current-year estimate revisions is positive, with six estimates moving higher and no negative revisions [7] Zacks Rank - Alnylam currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions that can guide investment decisions [8] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8] Bottom Line - Investors have shown confidence in Alnylam due to solid estimate revisions, reflected in a 21.1% stock gain over the past four weeks, suggesting potential for further growth [9]

Core Viewpoint - The market anticipates Alnylam Pharmaceuticals (ALNY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - Alnylam is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year change of -105.4% [3]. - Revenues are projected to be $671.11 million, which is a 1.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 62.96% higher in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +831.25% suggests that analysts have recently become more optimistic about Alnylam's earnings prospects [12]. Earnings Surprise History - In the last reported quarter, Alnylam was expected to post a loss of $0.56 per share but actually reported a loss of -$0.01, resulting in a surprise of +98.21% [13]. - Over the past four quarters, Alnylam has beaten consensus EPS estimates three times [14]. Industry Comparison - Incyte (INCY), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $1.4 per share for the same quarter, indicating a year-over-year change of +176.9% [18]. - Incyte's revenues are expected to reach $1.15 billion, up 10.3% from the previous year [18].

Core Viewpoint - Alnylam Pharmaceuticals (ALNY) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Performance - The Zacks rating system focuses on a company's changing earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to assess fair value [5]. Recent Developments for Alnylam - Alnylam's earnings estimates have seen a notable increase, with the Zacks Consensus Estimate for the fiscal year ending December 2025 rising by 52.6% [9]. - The upgrade to Zacks Rank 2 places Alnylam in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, ensuring that only the top 5% receive a "Strong Buy" rating [10].

Company Overview - Alnylam Pharmaceuticals (ALNY) is expected to report a year-over-year decline in earnings with a quarterly loss of $0.56 per share, reflecting a -250% change, while revenues are anticipated to be $587.72 million, an increase of 18.9% from the previous year [3][12]. Earnings Expectations - The consensus EPS estimate has been revised 5.17% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Earnings ESP for Alnylam is -12.28%, suggesting a lower Most Accurate Estimate compared to the Zacks Consensus Estimate, which complicates the prediction of an earnings beat [11][10]. Historical Performance - Alnylam has beaten consensus EPS estimates three times in the last four quarters, with a notable surprise of +128.57% in the last reported quarter [12][13]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, GSK is expected to report earnings of $1.08 per share, reflecting a -0.9% year-over-year change, with revenues projected at $9.54 billion, up 2.2% from the previous year [17]. - GSK's consensus EPS estimate has also been revised 1.9% lower, resulting in an Earnings ESP of -0.93%, making it difficult to predict an earnings beat [18].